glp-1 obesity drug market news today The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Study predicts 16 new obesity
Description
32 A recent systematic review and meta-analysis supporting these findings also showed that GLP-1 RA use was not associated with cholecystitis or gallstones in overweight/obese individuals without diabetes

The blood sugar benefits are excellent, and the weight loss is a meaningful bonus that improves overall diabetes management
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis

Risks: Increased heart rate, potential worsening of heart failure with reduced ejection fraction, and rare complications like hypoglycemia or retinopathy

In the same 2025 study by Qeadan and colleagues, individuals with a history of opioid use disorder (n=503,747) prescribed GLP-1 medications had about a 40% lower rate of opioid overdose events during the 2-year follow-up period (Qeadan et al., 2025)

Coming from low-dose semaglutide or tirzepatide
